Dako's Mission
-We fight cancer!
-As a world-leading expert, Dako continuously challenges and raises the global standards for fast and accurate answers for:
*Cancer Patients
*Doctors making vital decisions for treatment
Dako's Vision
-We want to be the first choice for pathology laboratories around the globe which strive to deliver the highest standards for speed and accuracy in cancer diagnostics
Global presence
History
Dako is one of business unit under Agilent Technologies Inc.
-We fight cancer!
-As a world-leading expert, Dako continuously challenges and raises the global standards for fast and accurate answers for:
*Cancer Patients
*Doctors making vital decisions for treatment
Dako's Vision
-We want to be the first choice for pathology laboratories around the globe which strive to deliver the highest standards for speed and accuracy in cancer diagnostics
Global presence
- Two major business areas: 1) Anatomic pathology, our primary strategic focus which accounts for 85% 2) Reagent Partnership Division which accounts for 15%
- Two manufacturing and research sites: - Glostrup, Denmark, - Carpinteria, California, USA
- More than 1,000 employees
- Global presence: - Sales offices in 20 countries - Distributors in more than 60 countries
- Owned by private equity fund EQT V
- 2010 revenues-- DKK 1.9 billion (~$340M USD)
History
- Founded in 1966 by the Danish medical doctor Niels Harboe
- Dako earned its reputation for innovation and quality by introducing the first conjugated antibodies for immunohistochemistry
- In 1998, Dako launched HercepTest™ as the first FDA-approved pharmDx™ product on the market
- Today, Dako provides solutions based on 45 years of experience in anatomic pathology
- Dako’s antibodies and reagents touch one in two of all specific tissue-based cancer tests worldwide.
Strength
- Leader with ~50% of the IHC reagent market by volume
- Most comprehensive range of antibodies with 95%+ coverage
- One of the largest installed bases of staining instruments
- Comprehensive suite of pharmaco-diagnostic (pharmDx™) reagent kits
- A strong R&D organization with 190 employees
- 14% of annual turnover invested in R&D
Area of Business
Cancer Diagnostics: Dako has more than 40 years of experience within pathology and has played a pioneering role in the standardization of antibodies. Dako has grown into a well-established global company with a leading position in the pathology segment of the in vitro diagnostics (IVD) industry.
Retail and OEM: Through Dako’s Reagent Partnership Division, Dako manages and sells a comprehensive portfolio of specific proteins and high-quality reagents for flow cytometry. In addition to the retail portfolio, RP sell monoclonal and polyclonal antibodies as bulk solutions to OEM customers.
Cancer Diagnostics: Dako has more than 40 years of experience within pathology and has played a pioneering role in the standardization of antibodies. Dako has grown into a well-established global company with a leading position in the pathology segment of the in vitro diagnostics (IVD) industry.
Retail and OEM: Through Dako’s Reagent Partnership Division, Dako manages and sells a comprehensive portfolio of specific proteins and high-quality reagents for flow cytometry. In addition to the retail portfolio, RP sell monoclonal and polyclonal antibodies as bulk solutions to OEM customers.
No comments:
Post a Comment